Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Commencement of NORSE EIGHT clinical trial in 2024 shows progress in the development of ONS-5010.
- Anticipated MAA decision date for ONS-5010 in the first half of 2024 indicates potential European approval.
- Reaffirmation of resubmission of the ONS-5010 BLA by the end of 2024 demonstrates commitment to achieve FDA approval.
- Reported net loss of $59.0 million for the fiscal year ended September 30, 2023, shows financial transparency.
- The net loss of $59.0 million for the fiscal year ended September 30, 2023, indicates financial challenges.
- Cash and cash equivalents of $23.4 million as of September 30, 2023, may raise concerns about liquidity.
Insights
The announcement by Outlook Therapeutics regarding the commencement of the ONS-5010 NORSE EIGHT clinical trial and the anticipated decision dates for regulatory approvals in Europe represents a pivotal moment for the company's strategic direction. The financial results indicating a net loss reduction and the extension of the maturity for the outstanding convertible promissory note suggest a critical juncture in the company's fiscal management and potential growth trajectory.
From a financial perspective, stakeholders should consider the implications of the company's cash position in relation to its burn rate and the upcoming milestones. The reduction in net loss year-over-year indicates improved fiscal discipline or cost efficiencies, which could be seen as a positive indicator for future financial performance. However, it is essential to monitor the company's capital requirements against the backdrop of these milestones to assess the likelihood of future financing needs or dilution.
The extension of the convertible note's maturity may provide short-term liquidity relief, but it also defers a potential conversion event that could impact shareholder equity. Investors should closely watch the terms of such conversions as they can influence the stock's valuation.
The initiation of the NORSE EIGHT clinical trial and the resubmission of the Biologics License Application (BLA) for ONS-5010 are critical steps towards potential FDA approval. The clinical trial's design, a non-inferiority study against ranibizumab, addresses a significant market need for an FDA-approved ophthalmic formulation of bevacizumab for retinal diseases. The outcome of this study will be a determinant factor in the drug's market potential and competitive positioning.
For stakeholders, the successful completion and positive results of the NORSE EIGHT trial could mean a substantial increase in the company's valuation due to the introduction of a new treatment option in a market with high demand. However, the inherent risks of clinical trials, including the possibility of negative outcomes or insufficient data for approval, must be factored into any assessment of the company's future prospects.
Furthermore, the anticipated decision by the European Medicines Agency (EMA) on the Marketing Authorization Application (MAA) in the first half of 2024 could open up additional markets and revenue streams for Outlook Therapeutics. The potential approval in Europe is a significant milestone that could bolster the company's international presence and commercial viability.
The biopharmaceutical sector is highly sensitive to regulatory milestones and Outlook Therapeutics' progress towards potential approvals in the U.S. and Europe is a testament to this. The ophthalmic formulation of bevacizumab represents a new entrant in the retinal disease treatment landscape, which is currently dominated by a few key players.
Understanding the competitive dynamics, the entry of ONS-5010 / LYTENAVA™ could disrupt existing market shares, particularly if it offers cost advantages or improved patient outcomes. The company's strategy to explore potential strategic partnerships and expanded relationships for international market penetration is indicative of a proactive approach to leveraging regulatory milestones for commercial success.
It is crucial to analyze the potential market size, pricing strategies and reimbursement scenarios to evaluate the long-term commercial viability of ONS-5010. The company's ability to navigate these factors successfully will be instrumental in determining its impact on the market and its financial performance post-approval.
- Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024
- Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application (MAA) decision date anticipated in the first half of 2024
- Resubmission of the ONS-5010 Biologics License Application (BLA) expected by the end of calendar year 2024
ISELIN, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve U.S. Food and Drug Administration (FDA) approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced recent corporate highlights and financial results for its fiscal year ended September 30, 2023.
“We remain committed to working with the FDA to design and undertake the additional clinical study for ONS-5010 that, if successful, will satisfy the FDA’s requirements for approval,” commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics. “The patient need for an ophthalmic approved bevacizumab remains and we are steadfast in our mission to meet this need.”
Upcoming Anticipated Milestones
- FDA response on NORSE EIGHT Special Protocol Assessment (SPA) in early February 2024;
- Commencement of NORSE EIGHT expected in first calendar quarter of 2024;
- MAA decision date in the EU for ONS-5010 expected targeted for first half of 2024;
- Completion of NORSE EIGHT in the U.S. anticipated in 2024; and
- Resubmission of the ONS-5010 BLA expected by the end of calendar year 2024.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Regulatory Update
As previously announced, following a Type A meeting with the FDA held in October 2023, the FDA informed Outlook Therapeutics that it can conduct a non-inferiority study evaluating ONS-5010 versus ranibizumab in a 3-month study of treatment naïve patients with a primary efficacy endpoint at 2 months. Subsequently, as discussed with and recommended by the FDA, Outlook Therapeutics submitted a clinical trial protocol and requested a Type A meeting with the FDA for feedback. The FDA has already provided written feedback on the protocol, which Outlook Therapeutics has incorporated. The revised protocol is the subject of the SPA request, in which Outlook Therapeutics is seeking further confirmation from the FDA that NORSE EIGHT, if successful, addresses the FDA’s requirement for a second adequate and well-controlled clinical trial to support the resubmission of the ONS-5010 BLA for wet AMD. The FDA is expected to provide a response to the SPA by early February 2024.
NORSE EIGHT will be a randomized, controlled, parallel-group, masked study of neovascular age-related macular degeneration subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 or 0.5 mg ranibizumab intravitreal injections. Subjects will receive injections at Day 0 (randomization), Week 4, and Week 8 visits. Approximately 400 patients are expected to be enrolled in the study.
Additionally, the Company previously announced that it submitted an MAA in Europe, which was validated for review in December 2022. The formal review process of the MAA by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is underway with an estimated decision date expected in the first half of 2024. In addition to pursuing potential strategic partnering opportunities in the EU and other regions, such as the current partnership with Syntone Biopharma JV in China, Outlook Therapeutics is also exploring potential expanded relationships with Cencora (formerly AmerisourceBergen) to support the launch of ONS-5010 in international markets.
If approved, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) will be the first FDA approved ophthalmic formulation of bevacizumab.
Financial Highlights for the 2023 Fiscal Year Ended September 30, 2023
For the fiscal year ended September 30, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of
As of September 30, 2023, Outlook Therapeutics had cash and cash equivalents of
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no FDA-approved ophthalmic formulations of bevacizumab are available currently, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 would provide an FDA-approved option for physicians that currently prescribe unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for the treatment of wet AMD.
Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to achieve FDA approval for the launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; the FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, Outlook Therapeutics and Cencora entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States. For more information, please visit www.outlooktherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “optimistic,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010’s potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, expectations concerning our ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including with respect to an additional clinical trial and CMC issues, expectations concerning the NORSE EIGHT trial design, the timing for initiation and completion of NORSE EIGHT and resubmission of the BLA for ONS-5010, expectations concerning decisions of regulatory bodies, including the FDA and EMA, and the timing thereof, plans for potential commercial launch of ONS-5010, expectations concerning the relationship with Cencora and the benefits and potential expansion thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by the FDA, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the “SEC”), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, to be filed with the SEC, and future quarterly reports we file with the SEC, which include uncertainty of future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflict, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
| Outlook Therapeutics, Inc. | |||||||
| Consolidated Statements of Operations | |||||||
| (Amounts in thousands, except per share data) | |||||||
| Year ended September 30, | |||||||
| 2023 | 2022 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 26,453 | $ | 42,331 | |||
| General and administrative | 26,673 | 20,740 | |||||
| 53,126 | - | 63,071 | |||||
| Loss from operations | (53,126 | ) | (63,071 | ) | |||
| Loss on equity method investment | 11 | 49 | |||||
| Interest expense, net | 1,560 | 1,487 | |||||
| Loss on extinguishment of debt | 578 | 1,025 | |||||
| Change in fair value of promissory notes | 3,756 | 883 | |||||
| Change in fair value of warrant liability | (51 | ) | (466 | ) | |||
| Loss before income taxes | (58,980 | ) | (66,049 | ) | |||
| Income tax expense | 3 | 3 | |||||
| Net loss attributable to common stockholders | $ | (58,983 | ) | $ | (66,052 | ) | |
| Per share information: | |||||||
| Net loss per share of common stock, basic and diluted | $ | (0.24 | ) | $ | (0.31 | ) | |
| Weighted average shares outstanding, basic and diluted | 250,177 | 212,079 | |||||
| Consolidated Balance Sheet Data | |||||||
| (Amounts in thousands) | |||||||
| September 30, | |||||||
| 2023 | 2022 | ||||||
| Cash and cash equivalents | |||||||
| Total assets | |||||||
| Current liabilities | |||||||
| Total stockholders' (deficit) equity | |||||||
FAQ
When is the commencement of the ONS-5010 NORSE EIGHT clinical trial?
What is the anticipated MAA decision date for ONS-5010 in the EU?
When is the resubmission of the ONS-5010 BLA expected?
What was the net loss for the fiscal year ended September 30, 2023?
What is the amount of cash and cash equivalents as of September 30, 2023?
